Filing Details

Accession Number:
0001209191-16-128063
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-06-15 19:02:34
Reporting Period:
2016-06-13
Filing Date:
2016-06-15
Accepted Time:
2016-06-15 19:02:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1423824 Alder Biopharmaceuticals Inc ALDR Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1604834 James Mark Litton 11804 North Creek Parkway South
Bothell WA 98011
Chief Business Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2016-06-13 1,900 $28.90 28,100 No 4 S Indirect Held in trust for the benefit of Reporting Person's minor child
Common Stock Disposition 2016-06-13 100 $29.60 28,000 No 4 S Indirect Held in trust for the benefit of Reporting Person's minor child
Common Stock Disposition 2016-06-13 1,900 $28.89 28,100 No 4 S Indirect Held in trust for the benefit of Reporting Person's minor child
Common Stock Disposition 2016-06-13 100 $29.60 28,000 No 4 S Indirect Held in trust for the benefit of Reporting Person's minor child
Common Stock Disposition 2016-06-13 1,800 $28.90 28,200 No 4 S Indirect Held in trust for the benefit of Reporting Person's minor child
Common Stock Disposition 2016-06-13 200 $29.64 28,000 No 4 S Indirect Held in trust for the benefit of Reporting Person's minor child
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect Held in trust for the benefit of Reporting Person's minor child
No 4 S Indirect Held in trust for the benefit of Reporting Person's minor child
No 4 S Indirect Held in trust for the benefit of Reporting Person's minor child
No 4 S Indirect Held in trust for the benefit of Reporting Person's minor child
No 4 S Indirect Held in trust for the benefit of Reporting Person's minor child
No 4 S Indirect Held in trust for the benefit of Reporting Person's minor child
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 74,567 Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by three trusts for the benefit of Reporting Person's minor children.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.45 to $29.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2 to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.43 to $29.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3 to this Form 4.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.45 to $29.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 to this Form 4.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.60 to $29.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 5 to this Form 4.